IQIRVO dosing
Recommended dose:
- Once-daily 80 mg dose, taken orally in adults with PBC, with or without food
- The tablet should not be crushed, chewed or split prior to administration.
No dose adjustment required:
- For patients with renal impairment
- For patients over 65 years of age
- For patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment
Hepatic impairment
- Use in patients with severe hepatic impairment (Child-Pugh C) is not recommended
- Prior to initiation of treatment with IQIRVO the patient’s hepatic status must be known.
In case of a missed dose:
- Patients should take the subsequent dose at the next scheduled time point. They should not take a double dose to make up for a missed dose
For full list of posology and dosing information, please refer to the SMPC before prescribing IQIRVO.
Abbreviation
PBC, primary biliary cholangitis.
Reference
- IQIRVO® (elafibranor) Summary of product characteristics (SmPC). 2024.
Resources
- PBC
- IQIRVO MoA
- The ELATIVE trial: Study design & baseline characteristics
- The ELATIVE trial: Efficacy
- The ELATIVE trial: Safety data
- IQIRVO Safety Data
- Dosing
- Resources